Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CVS Health Corporation (NYSE: CVS) securities between May 3, 2023 and April 30, 2024, inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the CVS class action lawsuit. Captioned Nixon v. CVS Health Corporation, No. 24-cv-05303 (S.D.N.Y.), the CVS class action lawsuit charges CVS as well as certain of CVS's top current and former executives with violations of the Securities Exchange Act of 1934.

CVS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that CVS Health Corporation Investors with Substantial Losses Have Opportunity to Lead Case

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVS Health Corporation Is Being Investigated By The Schall Law Firm Regarding Specific Allegations Investors Are Urged To Participate In The Inquiry

CVS Health (CVS) is grappling with a sudden increase in Medicare Advantage members' utilization trend. The Medicaid business, too, is expected to have experienced medical cost pressure in the second quarter.

CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?

Abbott Labs

Devon Energy

Helen of Troy

Hershey

Interpublic Group of Companies

Lamb Weston Hlds

PepsiCo

STMicroelectronics NV ADR RegS

Zimmer Biomet Hlds

Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.

10 Beaten-Up Blue Chips With Serious Turnaround Potential

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?

AMC Networks

Bumble

Avis Budget Group

Jack in the Box

Lithium Americas Argentina Corp

With the recent stock market pullback, you may be taking a look at potential bargains among widely-followed stocks. However, instead of “buying the dip” in what's popular, you may want to take a look at the deep value opportunities among contrarian stocks instead.

7 Contrarian Plays That Wall Street Is Ignoring: July 2024

NEW YORK , July 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

September 10, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against CVS

SAN DIEGO, July 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CVS Health Corporation (NYSE: CVS) securities between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the CVS class action lawsuit. Captioned Nixon v. CVS Health Corporation, No. 24-cv-05303 (S.D.N.Y.), the CVS class action lawsuit charges CVS as well as certain of CVS's top current and former executives with violations of the Securities Exchange Act of 1934.

CVS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that CVS Health Corporation Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO--(BUSINESS WIRE)---- $CVS #CVSHealthCorporation--Robbins LLP is Investigating Allegations that CVS Health Corporation (CVS) Misled Investors Regarding its Business Prospects.

Shareholder Rights Law Firm Robbins LLP Reminds CVS Stockholders with Large Losses They Can Lead the Class Action Against CVS Health Corporation

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Investors Can Lead CVS Health Corporation Securities Fraud Lawsuit With The Schall Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses.

CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=92430&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on CVS Health Corporation (CVS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit.

CVS Health Corporation Sued for Securities Law Violations – Contact Levi & Korsinsky Before September 10, 2024 to Discuss Your Rights – CVS

AutoZone

Ulta Beauty

While the overall market hovers near an all-time high, retail stocks lagged. Take the SPDR S&P Retail ETF (NYSEARCA: XRT ), for instance, the largest ETF in the space, which has yet to reclaim its 2021 highs.

3 Retail Stocks to Buy on the Dip: July 2024

SAN DIEGO, CA / ACCESSWIRE / July 24, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CVS Health Corporation (NYSE:CVS) securities between May 3, 2023 and April 30, 2024, both dates inclusive (the "Class Period"), have until September 10, 2024 to seek appointment as lead plaintiff of the CVS class action lawsuit. Captioned Nixon v.

CVS INVESTOR ALERT: CVS Health Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP  reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired CVS Health Corporation (NYSE: CVS) securities between May 3, 2023 and April 30, 2024. CVS is a healthcare company.

CVS Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the CVS Health Corporation Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Investors Have The Opportunity To Lead CVS Health Corporation Securities Fraud Lawsuit With The Schall Law Firm

CVS Caremark pledges to accelerate transparency, drive to lowest net cost prescription drugs, strengthen pharmacy relations, and deliver the best clinical care in pharmacy WOONSOCKET, R.I. , July 23, 2024 /PRNewswire/ -- CVS Caremark®, the nation's leading pharmacy benefit manager and a CVS Health® (NYSE: CVS) company, today announced a renewed pledge to American businesses, unions, and health plans — building on what the company is doing to deliver greater transparency, lower drug costs, and better clinical care for the most utilized health benefit.

CVS Caremark® defines future of pharmacy benefit management

LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVS Health Corporation Is Under Investigation By The Schall Law Firm Over Certain Claims Investors Are Encouraged To Join The Probe

Walgreens

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS and Walgreens and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=91663&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds CVS Health Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 – CVS

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS).

Shareholders of CVS Health Corporation Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights – CVS

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning CVS business and prospects, resulting in its stock trading at inflated prices.

CVS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that CVS Health Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for CVS Health Stock (CVS)